PIP
AMRI

Permian Investment Partners’s Albany Molecular Research Inc AMRI Stock Holding History

Permian Investment Partners’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Hold
0
– -$58K – 19
2015
Q1 		– Hold
0
– – – 15

Other funds holding AMRI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Permian Investment Partners's AMRI Position: Q2 2017 in Review

Permian Investment Partners sold out of Albany Molecular Research Inc (AMRI) in Q2 2017, closing a stake of 3,181,577 shares — an estimated $44.6M sold.

Permian Investment Partners first reported a position in AMRI in Q2 2014 and held it in 12 quarters. The position peaked at $62.6M in Q4 2016. 136 funds tracked by Wall St. Rank hold AMRI as of Q2 2017.

  • Permian Investment Partners reported no remaining Albany Molecular Research Inc position as of Q2 2017 after selling out during the quarter.
  • Permian Investment Partners sold 3,181,577 Albany Molecular Research Inc shares in Q2 2017, an estimated $44.6M.
  • Permian Investment Partners first reported a position in Albany Molecular Research Inc in Q2 2014 and held it in 12 quarters.
  • Permian Investment Partners's Albany Molecular Research Inc position peaked at $62.6M in Q4 2016.
  • 136 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2017.

Based on Permian Investment Partners's 13F filing for Q2 2017, filed 14 Aug 2017.